Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 3.87 times its current sales, is high.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
BRISTOL-MYERS SQUIBB COMPAN..-6.96%135 331
JOHNSON & JOHNSON1.97%391 896
ROCHE HOLDING AG5.96%295 228
PFIZER, INC.-2.53%212 139
MERCK & CO., INC.-11.25%203 745
NOVARTIS AG-9.65%190 274
ABBVIE INC.4.66%163 660
NOVO NORDISK A/S12.83%152 054
ASTRAZENECA PLC14.13%138 964
ELI LILLY AND COMPANY16.37%138 642
AMGEN INC.-4.72%135 120
SANOFI SA-2.33%121 900
GLAXOSMITHKLINE PLC-7.11%102 688
CHUGAI PHARMACEUTICAL CO., ..57.64%80 786
BAYER AG-16.60%66 318
ALLERGAN PLC0.97%63 659
More Results
Financials (USD)
Sales 2020 41 932 M - -
Net income 2020 1 114 M - -
Net Debt 2020 27 322 M - -
P/E ratio 2020 114x
Yield 2020 2,99%
Capitalization 135 B 135 B -
EV / Sales 2019
EV / Sales 2020 3,87x
Nbr of Employees 30 000
Free-Float 77,3%
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes